(Approval lapsed) BCG-medac, powder and solvent for suspension for intravesical use
Section 19A approved medicine
(Approval lapsed) BCG-medac, powder and solvent for suspension for intravesical use
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
ONCOTICE BCG 5 hundred million CFU powder for injection vial - ARTG 59912
Indication(s)
Treatment of primary or recurrent carcinoma in situ (CIS) of the urinary bladder. Intravesical BCG is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA [grade 2 or 3] or T1 [grade 1, 2, or 3]). Intravesical BCG is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence.